{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-003908","form_type":"8-K","ticker":null,"cik":"0001900520","company_name":"Lomond Therapeutics Holdings, Inc.","filed_at":"2026-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.717588+00:00","generated_at":"2026-05-16T10:43:12.786304+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lomond invests $9M in Idwal Therapeutics for Series A preferred units; option for $2M additional","bullets":["Lomond purchased 3.1M Series A Preferred Units of Idwal at $2.90/unit for ~$9.0M; closing occurred Jan 8, 2026.","Idwal formed with MALT-1 program assets from Tegid Therapeutics; total gross proceeds ~$47M from all investors.","Lomond has option to invest additional ~$2.0M on same terms.","Initial managers of Idwal are Lomond's directors: Iain Dukes, Nikolay Savchuk, Carl Gordon, Eddie Wang Rodriguez."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-003908","json":"https://secwatch.observer/filing/0001213900-26-003908.json","markdown":"https://secwatch.observer/filing/0001213900-26-003908.md","text":"https://secwatch.observer/filing/0001213900-26-003908.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1900520/000121390026003908/0001213900-26-003908-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1900520/000121390026003908/ea0272638-8k_lomond.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:43:12.786304+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"04dfac786879177d26ec5aa4fc28dd6cf0893db2","claim":"Lomond Therapeutics Holdings, Inc. entered into Series A Preferred Unit Purchase Agreement with Idwal Therapeutics, LLC valued at approximately $9.0 million (effective 2026-01-08).","evidence_excerpt":"On January 8, 2026, Lomond Therapeutics Holdings, Inc. (the “Company”) entered into a Series A Preferred Unit Purchase Agreement (the “Purchase Agreement”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1900520/000121390026003908/0001213900-26-003908-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Idwal Therapeutics, LLC"},{"label":"Value","value":"approximately $9.0 million"},{"label":"Effective","value":"2026-01-08"}],"fact_type":"material_agreement"},{"claim_id":"3f25fce25d67c3d864defc61b32d613125dda5a7","claim":"Lomond Therapeutics Holdings, Inc. entered into Amended and Restated Limited Liability Company Agreement with Idwal Therapeutics, LLC (effective 2026-01-08).","evidence_excerpt":"greement”) and related Amended and Restated Limited Liability Company Agreement (the “A&R LLC Agreement”) as an investor in Idwal Therapeutics, LLC (“Idwal”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1900520/000121390026003908/0001213900-26-003908-index.htm","confidence":0.85,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Idwal Therapeutics, LLC"},{"label":"Effective","value":"2026-01-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}